Status:
ACTIVE_NOT_RECRUITING
The Study of Transcranial Magnetic Stimulation in the Regulation of Spinocerebellar Ataxia
Lead Sponsor:
First Affiliated Hospital of Chongqing Medical University
Conditions:
Spinocerebellar Ataxia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Spinocerebellar ataxia (SCA) is a group of hereditary neurological diseases caused by gene mutations leading to degenerative changes in the cerebellum, brainstem, and spinal cord. A key pathogenic mec...
Eligibility Criteria
Inclusion
- Spinocerebellar ataxia patients confirmed through genetic testing
- Patient aged 18-75
- Patients who can walk independently (with the aid of a cane/walker) without assistance from others.
- The SARA score exceeds 3.
Exclusion
- Patients with unstable neurological disorders or accompanying medical conditions (such as stroke, arthritis, etc.)
- Patients with significantly abnormal clinical indicators identified during screening
- Patients concurrently participating in another clinical study
- Patients with untreated intracranial hypertension, depression, dementia, or psychiatric disorders
- Patients with severe heart disease
- Patients who are wheelchair users
- pregnant woman
- Patients who cannot establish their identity or have limited legal capacity
- Patients with contraindications for rTMS, including metallic objects in the head, history of neurosurgery, ferromagnetic bioimplants, metal coatings, history of seizures, autism, current use of protease inhibitors or other medications that may increase the risk of rTMS-induced seizures.
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06904716
Start Date
May 1 2023
End Date
May 1 2025
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliatted Hospital of Chongqing medical Uiversity
Chongqing, Chongqing Municipality, China, 400042